Arecor Therapeutics (LON:AREC) Stock Falls 1.5% – What’s Next?

Arecor Therapeutics plc (LON:AREC) shares fell 1.5% on Friday. The company traded as low as GBX 81.25 and last traded at GBX 81.25. 1,465 shares traded hands during trading, a decline of 94% from the average daily volume of 26,433 shares. The stock had previously closed at GBX 82.50.

Arecor Therapeutics Stock Performance

The company has a current ratio of 4.29, a quick ratio of 6.24 and a debt-to-equity ratio of 1.55. The company’s 50-day simple moving average is GBX 77.26 and its 200-day simple moving average is GBX 69. The stock has a market capitalization of £30.68 million, a price-to-earnings ratio of 81.25 and a beta of -0.18.

Arecor Therapeutics (LON:AREC) last released its quarterly earnings results on Thursday, October 1st. The company reported GBX (8) earnings per share (EPS) for the quarter. Arecor Therapeutics had a negative net margin of 200.00% and a positive return on equity of 3.75%. On average, analysts expect that Arecor Therapeutics plc will post -0.35 EPS for the current year.

About Arecor Therapeutics

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.